Table 1.
New Standards for Clear Cell RCC Therapy
| Setting | Phase 3 | Alternative |
|---|---|---|
| First-line therapy | ||
| Good or intermediate riskb | Sunitinib or bevacizumab plus interferon | High-dose IL-2 |
| Poor riskb | Temsirolimus | Sunitinib |
| Second-line therapy | ||
| Prior cytokine | Sorafenib | Sunitinib or bevacizumab |
| Prior VEGFR inhibitor | RAD001 | Clinical trials |
| Prior mTOR inhibitor | Clinical trials | Clinical trials |
Abbreviations: IL-2, interleukin 2; VEGFR, vascular endothelial growth factor receptor.
b
Memorial Sloan-Kettering Cancer Center risk status.